Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endo...
Verana Health®, a digital health company dedicated to revolutionizing patient care and clinical research through real-world data (RWD), has ann...
HERNEXEOS® (zongertinib) and JASCAYD® (nerandomilast) launched in H2, 2025 Group net sales increased 7.3%* to EUR 27.8 billion in 2025 R&...
SK pharmteco, a leading global contract development and manufacturing organization (CDMO), and Prozomix, a pioneer in enzyme discovery and diversity,...
Gilead Sciences, Inc. (Nasdaq: GILD) announced it has entered into a definitive agreement to acquire Ouro Medicines, a privately held biotechnology...
New “Danaher Beacon,” first in the European Union, aims to accelerate translation, scalability, and reliability across cell and gene therap...
HUTCHMED (China) announces that it has initiated a registrational Phase III clinical trial of HMPL-760 in combination with R-GemOx (rituximab, gemcitabin...
In the U.S., FDA approval establishes Opdivo in combination with doxorubicin, vinblastine and dacarbazine (AVD) as the first immunotherapy combination ...
Belief BioMed announced that BBM-H901 (generic name: Dalnacogene Ponparvovec Injection), has been officially approved by the Pharmaceutical Adminis...
For the primary endpoint, retatrutide lowered A1C by an average of 1.7% to 2.0% across doses at 40 weeks in TRANSCEND-T2D-1 Participants taking retatrut...
Ractigen Therapeutics, a pioneering clinical-stage biotechnology company developing innovative small activating RNA (saRNA) therapeutics, announced that ...
Congruence Therapeutics announced that the first participant has been dosed in its Phase 1/1b clinical trial evaluating CGX-926, an oral small-mole...
Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at comme...
Primary endpoint met in Phase 3 TALAPRO-3 study demonstrating a statistically significant and clinically meaningful reduction in risk of disease prog...
© 2026 Biopharma Boardroom. All Rights Reserved.
